Aqueous humour interleukin-6 and vision outcomes with anti-vascular endothelial growth factor therapy
Author:
Sepah Yasir Jamal, Do Diana V., Mesquida Marina, Day Bann-Mo, Blotner Steven, Afridi Rubbia, Halim Muhammad Sohail, Hong Kyu, Wakshull Eric, Fauser Sascha, Stoilov Ivaylo, Dong Nguyen QuanORCID, , Abraham P., Alfaro D. V., Antoszyk A., Antworth M., Baker B., Baker C., Balles M., Boyer D., Bridges W., Brown D. M., Busbee B., Busquets M., Chan C., Chaudhry N., Chen S., Christoforidis J., Ciulla T., Clark W. L., Cleland T., Connor T., Daccache A., Dessouki A., Diddie K., Doft B., Dreyer R., Faber D. W., Feiner L., Feldman R., Ferrone P., Fox G., Foxman S., Frenkel R., Fung A., Gallemore R., Ghuman T., Gonzalez V., Gordon A., Gordon C., Gupta S., Hariprasad S., Heier J., Ho A., Holmes D., Huang J., Hubschman J. P., Hudson H., Ie D., Johnson R., Katz R., Kiss S., Kitchens J., Kokame G., Lit E., Liu M., Luu J. K., MacCumber M., Madreperla S., Marcus D., Martidis A., Martinez J., Michels M., Miller D., Morse L., Nasir M., Nguyen Q., Oliver S., Olsen K., Patel S., Pavan P., Pearlman J., Prenner J., Regillo C., Reichel E., Rosa R., Rose S., Sadda S., Samuel M., Singerman L., Singer M., Singh R., Stoller G., Suner I., Tabassian A., Taney B., Thach A., Thomas M., Tolentino M., Tom D., Tornambe P., Torti R., Truong S., Verstraeten T., Wagner A., Wald K., Weber P., Weishaar P., Wieland M., Williams D., Wong T., Wood M., Wroblewski J., Zhang K., , Do D. V., Lit E., Kruger E., Pollack J., Halperin L., Bennett M., Boyer D., Callanan D., Zhang K., Symons A., Abraham P.
Abstract
Abstract
Background
This analysis evaluated aqueous humour (AH) interleukin (IL)-6 concentrations and the association between AH IL-6 and visual outcomes in patients with neovascular age-related macular degeneration (nAMD) or diabetic macular oedema (DMO) receiving anti–vascular endothelial growth factor (VEGF) monotherapy.
Methods
Post hoc analysis of the multicentre, double-masked, randomised HARBOR (NCT00891735) and READ-3 (NCT01077401) trials. HARBOR enrolled treatment-naïve nAMD patients. READ-3 enrolled treatment-naïve/previously treated DMO patients. HARBOR patients received ranibizumab 0.5 or 2.0 mg monthly or as needed; AH samples were collected at month 2, after two previous intravitreal injections. READ-3 patients received ranibizumab 0.5 or 2.0 mg as needed; AH samples were collected at baseline and months 3, 6, 9, and 12. Main outcome measure: association between AH IL-6 concentrations and month 24 best-corrected visual acuity (BCVA).
Results
In both trials (HARBOR, N = 36; READ-3, N = 137), patients with higher AH IL-6 concentrations had worse visual outcomes. HARBOR patients with low AH IL-6 concentrations at month 2 had a mean (95% CI) BCVA change at month 24 of +2.9 (−2.6, 8.3) letters, whereas patients with high AH concentrations had a mean (95% CI) BCVA change of −9.0 (−22.7, 4.7) letters. READ-3 patients with low AH concentrations at baseline had a mean (95% CI) BCVA change at month 12 of +9.3 (7.4, 11.3) letters, whereas patients with high AH concentrations had a mean (95% CI) BCVA change of +5.6 (2.2, 9.1) letters.
Conclusions
Higher IL-6 AH concentrations may predict suboptimal visual responses to anti–VEGF monotherapy in patients with nAMD/DMO.
Funder
Genentech Juvenile Diabetes Research Foundation
Publisher
Springer Science and Business Media LLC
Reference42 articles.
1. Tanaka T, Narazaki M, Kishimoto T. IL-6 in inflammation, immunity, and disease. Cold Spring Harb Perspect Biol. 2014;6:a016295. 2. Mesquida M, Leszczynska A, Llorenç V, Adán A. Interleukin-6 blockade in ocular inflammatory diseases. Clin Exp Immunol. 2014;176:301–9. 3. Rezar-Dreindl S, Sacu S, Eibenberger K, Pollreisz A, Bühl W, Georgopoulos M, et al. The intraocular cytokine profile and therapeutic response in persistent neovascular age-related macular degeneration. Investig Ophthalmol Vis Sci. 2016;57:4144–50. 4. Feng J, Zhao T, Zhang Y, Ma Y, Jiang Y. Differences in aqueous concentrations of cytokines in macular edema secondary to branch and central retinal vein occlusion. PLoS ONE. 2013;8:e68149. 5. Minaker SA, Mason RH, Bamakrid M, Lee Y, Muni RH. Changes in aqueous and vitreous inflammatory cytokine levels in retinal vein occlusion: a systematic review and meta-analysis. J VitreoRetin Dis. 2020;4:36–64.
|
|